The next course an "Update on Pharmacoeconomics in the Irish Healthcare Setting" will take place on 15th & 16th May 2019 in Dublin Castle. Places now available. Please click here for registration form and course programme.
The NCPE recommends that daratumumab combination (Darzalex®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The NCPE recommends that liraglutide (Victoza®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.